Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia

European Journal of Haematology

Volumn 73, Issue 3, 2004, Pages 191-205

  Ito, Kinro ^a   Tanaka, Hideo ^a   Ito, Takuo ^a   Sultana, Tanvira A ^a   Kyo, Taiichi ^b   Imanaka, Fumio ^c   Ohmoto, Yasukazu ^d   Kimura, Akiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^c HIROSHIMA CITY ASA HOSPITAL   (Japan)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Chronic myelogenous leukemia; Down regulation; Interferon; Receptor

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ALPHA INTERFERON RECEPTOR TYPE 1; ALPHA INTERFERON RECEPTOR TYPE 2; CD34 ANTIGEN; MESSENGER RNA; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD34; BONE MARROW CELLS; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 4043060650     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00275.x     Document Type: Article

References (52)

1. FADEREL S, TALPAZ M, ESTROV Z, KANTARJIAN HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-219.
2. OHNISHI K, OHNO R, TOMONAGA M, KAMADA N, ONOZAWA K, KURAMOTO A, DOHY H, MIZOGUCHI H, MIYAWAKI S, TSUBAKI K. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86:906-916.
3. KANTARJIAN HM, SMITH TL, O'BRIEN S, BERAN M, PIERCE S, TALPAZ M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995;122:254-261.
4. GOLDMAN JM. Treatment of chronic myeloid leukaemia: lessons and challenges. Int J Hematol 2002;76 (Suppl 2):189-192.
5. KANTARJIAN HM, SAWYERS C, HOCHHAUS A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-652.
6. KANTARJIAN HM, CORTES JE, O'BRIEN S et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003;101:97-100.
7. BARTHE C, GHARBI MJ, LAGARDE V, CHOLLET C, CONYMAKHOUL P, REIFFERS J, GOLDMAN JM, MELO JV, MAHON FX. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br J Haematol 2002;119:109-111.
8. BRAZIEL RM, LAUNDER TM, DRUKER BJ, OLSON SB, MAGENIS RE, MAURO MJ, SAWYERS CL, PAQUETTE RL, O'DWYER ME. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002;100:435-441.
9. KANO Y, AKUTSU M, TSUNODA S, MANO H, SATO Y, HONMA Y, FURUKAWA Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001;97:1999-2007.
10. VERMA A, PLATANIAS LC. Signaling via the interferon-α receptor in chronic myelogenous leukemia cells. Leuk Lymphoma 2002;43:703-709.
11. GRUMBACH IM, MAYER IA, UDDIN S, LEKMINE F, MAJCHRZAK B, YAMAUCHI H, FUJITA S, DRUKER B, FISH EN, PLATANIAS LC. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells. Br J Haematol 2001;112:327-336.
12. MAYER IA, VERMA A, GRUMBACH IM, UDDIN S, LEKMINE F, RAVANDI F, MAJCHRZAK B, FUJITA S, FISH EN, PLATANIAS LC. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-α in BCR-ABL-expressing cells. J Biol Chem 2001;276:28570-28577.
13. HOCHHAUS A, YAN XH, WILLER A, HEHLMANN R, GORDON MY, GOLDMAN JM, MELO JV. Expression of interferon regulatory factor (IRF) genes and response to interferon-α in chronic myeloid leukaemia. Leukemia 1997,11:933-939.
14. SCHMIDT M, HOCHHAUS A, KÖNIG-MEREDIZ SA, BRENDEL C, PROBA J, HOPPE GJ, WITTIG B, EHNINGER G, HEHLMANN R, NEUBAUER A. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: Correlation with response to interferon alfa therapy. J Clin Oncol 2000;18:3331-3338.
15. SCHMIDT M, HOCHHAUS A, NITSCHE A, HEHLMANN R, NEUBAUER A. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-α. Blood 2001;97:3648-3650.
16. MOLLDREM JJ, LEE PP, WANG C, FELIO K, KANTARJIAN HM, CHAMPLIN RE, DAVIS MM. Evidence that T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-1023.
17. MOLLDREM JJ, LEE PP, KANT S, WIEDER E, JIANG W, LU S, WANG C, DAVIS MM. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidty leukemia-specific T cells. J Clin Invest 2003;111:639-647.
18. BCR/ABL protein are downmodulated by interferon-α in chronic myeloid leukemia patients. Blood 1999;94:2200-2207.
19. KAWAISHI K, KIMURA A, KATOH O, SASAKI A, OGUMA N, IHARA A, SATOW Y. Decreased L-selectin expression in CD34-positive cells from patients with chronic myelocyic leukemia. Br J Haematol 1996;93:367-374.
20. STARK GR, KERR IM, WILLIAMS BRG, SILVERMAN RH, SCHREIBER RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264.
21. ORITANI K, MEDINA K, TOMIYAMA Y et al. Limitin: an interferon-like cytokine that preferentially influences B-lymphocyte precursors. Nature Med 2000;6:659-666.
22. UZÉ G, LUTFALLA G, GRESSER I. Genetic transfer of a functional human interferon-α receptor into mouse cells: cloning and expression of its cDNA. Cell 1990;60:225-234.
23. NOVICK D, COHEN B, RUBINSTEIN M. The human interferon αβ receptor: characterization and molecular cloning. Cell 1994;77:391-400.
24. MOGENSEN KE, LEWERENZ M, REBOUL J, LUTFALLA G, UZÉ G. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res 1999;19:1069-1098.
25. PREJEAN C, COLAMONICI OR. Role of the cytoplasmic domains of the type I interferon receptor subunits in signaling. Semin Cancer Biol 2000;10:83-92.
26. LUTFALLA G, HOLLAND S, CINATO E et al. Mutant U5A cells are complemented by an interfereron-αβ receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 1995;14:5100-5108.
27. DOMANSKI P, WITTE M, KELLUM M, RUBINSTEIN M, HACKETT R, PITHA P, COLAMONICI O. Cloning and expression of a long form of the β subunit of the intereferon αβ receptor that is required for signaling. J Biol Chem 1995;270:21606-21611.
28. KOTENKO SV, IZOTOVA LS, MIROCHNITCHENKO OV, LEE C, PESTKA S. The intracellular domain of interferon-α receptor 2c (IFN-αR2c) chain is responsible for Stat activation. Proc Natl Acad Sci USA 1999;96:5007-5012.
29. BILLARD C, SIGAUX F, CASTAIGNE S, VALENSI F, FLANDRIN G, DEGOS L, FALCOFF E, AGUET M. Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells. Blood 1986;67:821-826.
30. BILLARD C, FERBUS D, DIEZ RA, KOLB J, MATHIOT C, BELANGER C, AUZANNEAU G, VARET B, FALCOFF E, DUMONT J. Correlation between the biological and therapeutic effects of interferon-alpha in low-grade nodular non-Hodgkin's lymphoma: lack of in vivo down-regulation and reduced affinity of IFN-α receptors in unresponsive patients. Leukemia Res 1991;15:121-128.
31. MAXWELL BL, TALPAZ M, GUTTERMAN JU. Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFNα) therapy. Int J Cancer 1985;36:23-28.
32. ROSENBLUM MG, MAXWELL BL, TALPAZ M, KELLEHER PJ, MCCREDIE KB, GUTTERMAN JU. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2′,5′-oligoadenylate synthetase. Cancer Res 1986;46:4848-4852.
33. BARTSCH H, PFIZENMAIER K, HANUSCH A, SCHEURICH P, ÜCER U, NAGEL G. Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: Clinical responsiveness to recombinant IFN-α correlates with the degree of receptor down-regulation. Int J Cancer 1989;43:235-240.
34. BARTHE C, MAHON F-X, GHARBI M-J, FABERES C, BILHOU-NABERA C, HOCHHAUS A, REIFFERS J, MARIT G. Expression of interferon-α (IFN-α) receptor 2c at diagnosis is associated with cytogenetic response in IFN-α-treated chronic myeloid leukemia. Blood 2001;97:3568-3573.
35. GIRON-MICHEL J, WEILL D, BAILLY G, LEGRAS S, NARDEUX PC, AZZARONE B, TOVEY MG, EID P. Direct signal transduction via functional interferon- αβ receptors in CD34+ hematopoietic stem cells. Leukemia 2002;16:1135-1142.
36. MARTYRE MC, WIETZERBIN J. Characterization of specific functional receptors for HuIFN-α on a human megakaryocytic cell line (Dami): expression related to differentiation. Br J Haematol 1994;86:244-252.
37. FANTUZZI L, EID P, MALORNI W, RAINALDI G, GAUZZI MC, PELLEGRINI S, BELARDELLI F, GESSANI S. Post-translational up-regulation of the cell surface-associated alpha component of the human type I interferon receptor during differentiation of peripheral blood monocytes: role in the biological response to type I interferon. Eur J Immunol 1997;27:1075-1081.
38. TALPAZ M, MCCREDIE K, KANTARJIAN HM, TRUJILLO JM, KEATING MJ, GUTTERMAN JU. Chronic myelogenous leukaemia: Haemtological remissions with with alpha interferon. Br J Haematol 1986;64:87-95.
39. SEABRIGHT M. A rapid banding technique for human chromosomes. Lancet 1971;2:971-972.
40. TAKAYAMA A, YANO H, OGASAWARA S, HIGAKI K, KOJIRO M. Expression of Hu-IFN-αR2 chain of type I interferon receptor in human hepatocellular carcinoma and non-cancerous tissues. Int J Mol Med 2000;6:621-627.
41. MIZUKOSHI E, KANEKO S, KAJI K, TERASAKI S, MATSUSHITA E, MURAGUCHI M, OHMOTO Y, KOBAYASHI K. Serum levels of soluble interferon alfa/beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C. Hepatology 1999;30:1325-1331.
42. DADMARZ R, EVANS T, SECHER D, MARSHALL N, CAWLEY JC. Hairy cells possess more interferon receptors than other lymphoid cell types. Leukemia 1987;1:357-361.
43. DUPONT SA, GOELZ S, GOYAL J, GREEN M. Mechanism for regulation of cellular responsiveness to human IFN-β1a. J Interferon Cytokine Res 2002;22:491-501.
44. COLAMONICI OR, PORTERFIELD B, DOMANSKI P, CONSTANTINESCU S, PFEFFER LM. Complementation of the interferon alpha response in resistant cells by expression of the cloned subunit of the interferon α receptor. A central role of this subunit in interferon α signaling. J Biol Chem 1994;269:9598-9602.
45. GAUZZI MC, CANINI I, EID P, BELARDELLI F, GESSANI S. Loss of type I IFN receptors and impaired IFN responsiveness during terminal maturation of monocyte-derived human dendritic cells. J Immunol 2002;169:3038-3045.
46. WU C-Y, WARRIER RR, WANG X, PRESKY DH, GATELY MK. Regulation of interleukin-12 receptor β1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells. Eur J Immunol 1997;27:147-154.
47. HARDY MP, HERTZOG PJ, OWCZAREK CM. Multiple regions within the promoter of the murine Ifnar-2 gene confer basal and inducible expression. Biochem J 2002;365:355-367.
48. RAGIMBEAU J, DONDI E, ALCOVER A, EID P, UZÉ G, PELLEGRINI S. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J 2003;22:537-547.
49. MELLMAN I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 1996;12:575-625.
50. CONSTANTINESCU SN, CROZE E, MURTI A et al. Expression and signaling specificity of the IFNAR chain of the type I interferon receptor complex. Proc Natl Acad Sci USA 1995;92:10487-10491.
51. NOVICK D, COHEN B, RUBINSTEIN M. Soluble interferon-alpha receptor molecules are present in body fluids. FEBS Lett 1992;314:445-448.
52. HARDY MP, OWCZAREK CM, TRAJANOVSKA S, LIU X, KOLA I, HERTZOG PJ. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 2001;97:473-482.